ACC.26 Día 3 (Parte 2)
Sobre este episodio
En este episodio de Cardiosíntesis, exploramos los ensayos clínicos más importantes de este tercer día en el ACC 2026 de Nueva Orleans. 1. Redo-Surgery Versus Transcatheter Valve-In-Valve For Mitral Bioprosthetic Dysfunction: The SURVIV Trial 2. The Heartline Experience: Achieving Long-Term Participant Engagement in Digital Health Technology Trials 3. Effect Of Anti-fibrotic Therapy On Regression Of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) In Aortic Stenosis Patients With High Fibrotic Burden: The Reduce-MFA DZHK 25-trial